SHStéphane Honoré

Stéphane Honoré

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Stéphane Honoré has a total of 16 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Low concentrations of vorinostat decrease EB1 expression in GBM cells and affect microtubule dynamics, cell survival and migration

    by Thomas Perez, Raphaël Bergès, Hélène Maccario, Sarah Oddoux, Stéphane Honoré

    Https://doi.org/10.18632/oncotarget.27892 Thomas Perez, Raphaël Bergès, Hélène Maccario, Sarah Oddoux, Stéphane Honoré


  • Open Access

    Microtubules (MT) a key target in oncology: mathematical modeling of anti-MT agents on cell migration

    by Emilie Denicolai, Stéphane Honoré, Florence Hubert, Rémi Tesson

    Microtubules (MTs) are protein filaments found in all eukaryotic cells which are crucial for many cellular processes including cell movement, cell differentiation, and cell division, making them a key target for anti-cancer treatment. In particular, it has been shown that at low dose, MT targeted agents (MTAs) may induce an anti-migratory effect on cancer and endothelial cells, leading to new prospects in cancer therapy. In that context, we propose to better understand the role of MT dynamics and thus of MTAs on cell migration using a mathematical cell centered model of cell migration taking into account the action of microtubules in the process. The model use a fluid based approach that describes, through level-set techniques, the deformation of the membrane during cell migration. The fluid part of the model is mainly composed of Stokes equations and the biochemical state of the cell is described using Reaction-Diffusion equations. Microtubules act on the biochemical state by activating or inactivating proteins of the Rho-GTPases family. The numerical simulation of the model is performed using Discrete Duality Finite Volume techniques. We describe the different schemes used for the simulation, focusing on the adaptation of preexisting methods to our particular case. Numerical simulation are performed, showing a realistic behavior of the simulated cells in term of shape, speed and microtubules dynamics. Different strategies for a depolymerizing MTA (Vincristin) mechanisms are investigated and show the robutness of our model.


  • Open Access

    Anti-Migratory Effect of Vinflunine in Endothelial and Glioblastoma Cells Is Associated with Changes in EB1 C-Terminal Detyrosinated/Tyrosinated Status

    by Amandine Rovini, Géraldine Gauthier, Raphaël Bergès, Anna Kruczynski, Diane Braguer, Stéphane Honoré

    We previously showed that vinflunine, a microtubule-targeting drug of the Vinca-alkaloid family exerted its anti-angiogenic/anti-migratory activities through an increase in microtubule dynamics and an inhibition of microtubule targeting to adhesion sites. Such effect was associated with a reduction of EB1 comet length at microtubule (+) ends. In this work we first showed that the pro-angiogenic vascular endothelial growth factor VEGF suppressed microtubule dynamics in living Human Umbilical Vein Endothelial Cells (HUVECs), increased EB1 comet length by 40%, and induced EB1 to bind all along the microtubules, without modifying its expression level. Such microtubule (+) end stabilization occurred close to the plasma membrane in the vicinity of focal adhesion as shown by TIRF microscopy experiments. Vinflunine completely abolished the effect of VEGF on EB1 comets. Interestingly, we found a correlation between the reduction of EB1 comet length by vinflunine and the inhibition of cell migration. By using 2D gel electrophoresis we demonstrated for the first time that EB1 underwent several post-translational modifications in endothelial and tumor cells. Particularly, the C-terminal EEY sequence was poorly detectable in control and VEGF-treated HUVECs suggesting the existence of a non-tyrosinated form of EB1. By using specific antibodies that specifically recognized and discriminated the native tyrosinated form of EB1 and a putative C-terminal detyrosinated form, we showed that a detyrosinated form of EB1 exists in HUVECs and tumor cells. Interestingly, vinflunine decreased the level of the detyrosinated form and increased the native tyrosinated form of EB1. Using 3-L-Nitrotyrosine incorporation experiments, we concluded that the EB1 C-terminal modifications result from a detyrosination/retyrosination cycle as described for tubulin. Altogether, our results show that vinflunine inhibits endothelial cell migration through an alteration of EB1 comet length and EB1 detyrosination/retyrosination cycle.


    • 1 December 2003
      • Vol. 2  (12) , 1303-11

    Suppression of microtubule dynamics by discodermolide by a novel mechanism is associated with mitotic arrest and inhibition of tumor cell proliferation.

    by Stéphane Honore, Kathy Kamath, Diane Braguer, Leslie Wilson, Claudette Briand, Mary Ann Jordan

    Discodermolide is a new microtubule-targeted drug in Phase I clinical trials that inhibits tumor growth and induces G(2)-M cell cycle arrest. It is effective against paclitaxel-resistant cell lines and acts synergistically in combination with paclitaxel. Suppression of microtubule dynamics by microtubule-targeted drugs has been hypothesized to be responsible for their ability to inhibit mitotic progression and cell proliferation. To determine whether discodermolide blocks mitosis by an effect on microtubule dynamics, we analyzed the effects of discodermolide on microtubule dynamics in living A549 human lung cancer cells during interphase at concentrations that block mitosis and inhibit cell proliferation. We found that discodermolide (7-166 nM) significantly suppressed microtubule dynamic instability. At the IC(50) for proliferation (7 nM discodermolide, 72 h), overall dynamicity was reduced by 23%. The principal parameters of dynamic instability suppressed by discodermolide were the microtubule shortening rate and length shortened. In addition, discodermolide markedly increased the frequency of rescued catastrophes. At the discodermolide concentration that resulted in 50% of maximal mitotic block (83 nM, 20 h), most microtubules were completely non-dynamic, no anaphases occurred, and all spindles were abnormal. The dynamicity of the remaining dynamic microtubules was reduced by 62%. The results indicate that a principal mechanism of inhibition of cell proliferation and mitotic block by discodermolide is suppression of microtubule dynamics. Importantly, the results indicate significant additional stabilizing effects of discodermolide on microtubule dynamics as compared with those of paclitaxel that may in turn reflect differences in their binding sites and their effects on tubulin conformation.